While infiltration of various cell types from the adaptive immune system (83) and other markers, such as tumor mutational burden (TMB) (84) or IFNG signature (75), have been associated with good prognosis and immunotherapy response in various cancer types, the suppressive immune environment with tumor-supportive CD68+CD163+ macrophages is becoming more important (66). Here, CD163 is linked to cancer.